TenX plans to consult both the FDA and EMA regarding the results of its clinical trials.
1 report, 1 independent
Updated Aug 11
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
TenX plans to consult both the FDA and EMA regarding the results of its clinical trials.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
TenX
A human centered design and technology studio.
Nothing else this week.
-
EMA
Japanese vocalist of the group DUSTCELL
Nothing else this week.
- FDA
Related events
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Anavex Life Sciences submitted data for FDA discussions and received scientific advice from the EMA.
- IGC Pharma, Inc. is preparing data for potential U.S. FDA review and seeking EMA support for its lead drug candidate.
- Jazz Pharmaceuticals received FDA approval for a drug following positive clinical trial results.
- FDA issued a partial clinical hold on trials involving Biohaven Ltd. on September 11, 2026.